Issue 28

Despite Asia’s rich history of psychedelic experience, the state of psychedelic study and commercial exploration varies widely across the continent.

While some countries are forging ahead with research, it appears formal research activity is non-existent in many regions of the continent, known for its traditional hard-line stance on psychedelics generally.

However, as the planet’s most populous continent, the potential scope of the medical psychedelic market and its possible impact on the region is extensive.

This two-part series will examine psychedelic history, current state, research efforts and business activity throughout Asia.

The potential for psychedelic drugs to transform healthcare is vast. In the Psychedelics as Medicine Report: Second Edition, PSYCH calculated the potential of psychedelic compounds to relieve economic burden.

In our assessments, we took into account factors including:

• direct medical costs such as the services and goods that are used or lost in managing diseases, from prevention to healthcare expenditures
• direct non-medical expenses such as informal care and social services
• indirect costs such as loss in days of work or loss of productivity for other reasons.

Assessments revealed potential healthcare savings in Europe alone amount to over US$130b. Learn more about our approach and the potential for global healthcare savings in the report.

Are you keeping up to date on the latest advancements in psychedelic science? Then join us on 7 July for the PSYCH Investor Summit: Research & Development, the must-attend virtual global event for investors and funds eyeing the most promising opportunities in psychedelics today.

Learn how research is paving the way for industry growth; discover the likely timeline for drug trials and commercialisation; and meet one-on-one with the groups and researchers leading the charge.